Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is Watching

Definium Therapeutics, Inc. (DFTX) has secured a second successful Phase 3 trial for its LSD-based medication DT120, aimed at treating generalized anxiety disorder. The 12-week study showed a 9.8-point reduction in anxiety scores compared to a 4.7-point decrease with a placebo, indicating a 5.1-point improvement. This result mirrors that of Definium's previous pivotal trial, Voyage, which demonstrated an 11.6-point improvement with LSD versus 6.2 with placebo.

Psychedelic stocks have historically demonstrated a tendency to trade together, with Definium's latest success likely boosting their collective performance. Hedge funds have shown increased interest in DFTX, with the number of funds holding the stock rising from 46 to 72 in the second quarter. This series of positive results for Definium across multiple indications significantly reduces the risk of an FDA approval and moves the company closer to submitting a New Drug Application.